Paul Eisenberg
About Paul Eisenberg
Paul Eisenberg: Chief Medical Officer and Venture Partner
Paul Eisenberg holds the title of Chief Medical Officer and Venture Partner. His professional trajectory illustrates a robust combination of leadership roles in both clinical and pharmaceutical development settings.
Paul Eisenberg's Education and Expertise
Paul Eisenberg earned his MD from New York Medical College. He further specialized by obtaining a Master's in Public Health in tropical medicine from the Tulane University School of Public Health and Tropical Medicine. His medical training includes specializations in internal medicine, cardiology, and pulmonary diseases at Washington University.
Paul Eisenberg's Academic and Professional Background
Paul Eisenberg served as a Professor of Medicine and Directed the Cardiac Intensive Care Unit at Barnes-Jewish Hospitals. His research has largely focused on the mechanisms of thrombosis in ischemic heart disease and response to fibrinolytic therapy. Additionally, he has contributed to the development of novel anti-thrombotic therapies.
Leadership Roles at Eli Lilly and Amgen
At Eli Lilly, Paul Eisenberg held several leadership roles, focusing on Cardiovascular Discovery and Translational Medicine, drug development and commercialization, and drug safety. Later, he led the Global Regulatory and Safety sector at Amgen and oversaw the Global Medical Affairs organization. His role significantly impacted the development and global registration of all Amgen products from 2006 through 2014. Additionally, he was a participant in PDUFA V negotiations representing Amgen.
Paul Eisenberg's Research and Publications
Paul Eisenberg has contributed significantly to academic research with 80 peer-reviewed publications of original research. Additionally, he has more than 40 contributions to reviews and books. His research work has been pivotal in understanding thrombosis in ischemic heart disease and the development of anti-thrombotic therapies.